Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PTHS
SellHot AirPelthos Therapeutics Inc. · Healthcare · United States · $95M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Pelthos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for infectious diseases and other unmet medical needs. The company's competitive position is anchored by its proprietary drug development platforms and targeted intellectual property portfolio. It operates as a specialized niche player in the biopharmaceutical sector, navigating clinical trials to bring first-in-class treatments to market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.8M | — | 43.3M | 63.7M | 112.2M | 158.5% |
| EPS | -0.44 | -2.12 | -2.51 | -23.04 | — | -28.63 | -18.82 | -5.68 | — |
| Shares | 3.5M | 3.5M | 3.5M | 3.2M | -6.9% | 3.8M | — | — | — |
| Debt | 0.5M | 1.3M | 2.2M | 34.8M | 300.9% | 73.1M | — | — | — |
| Equity | -3.7M | -6.4M | -2.7M | 38.9M | — | — | — | — | — |
| Op CF | -1.6M | -1.0M | -5.8M | -22.6M | — | -42.3M | — | — | — |
| Inv CF | — | — | 0 | -5.2M | — | — | — | — | — |
| Fin CF | 1.6M | 1.0M | 6.2M | 45.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTHS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc.(you) | $95M | 26 | Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
| SEER | Seer, Inc. | $110M | 28 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| MNOV | MediciNova, Inc. | $71M | 23 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%